Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709958 | 1.00 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL6378266 | 0.86 | PARP1 (1.00) | PARP1 | |
| Hydrochloric Acid SCHEMBL6790211 | 0.85 | PARP1 (0.98) | PARP1 | |
| SCHEMBL20738012 | 0.85 | PARP1 (0.73) | PARP1PARP2 | |
| SCHEMBL6795925 | 0.85 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL6791769 | 0.80 | PARP1 (1.00) | PARP1 | |
| SCHEMBL7704600 | 0.80 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL6800854 | 0.78 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL6796664 | 0.78 | PARP1 (0.84) | PARP1 | |
| SCHEMBL6801279 | 0.78 | PARP1 (0.81) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018022494-A1 | REPURPOSING CANCER DRUGS FOR TREATMENT OF MYCOBACTERIUM | STC.UNM (US) | 2018-02-01 | — | — | WO | claimed |
| US-9623008-B2 | Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers | STC.UNM (US) | 2017-04-18 | — | — | US | claimed |
| US-20160184356-A1 | ARSENIC-BASED TREATMENT OF CANCERS AND INFLAMMATORY DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | claimed |
| US-20160051517-A1 | TARGETING ABNORMAL DNA REPAIR IN THERAPY-RESISTANT BREAST AND PANCREATIC CANCERS | STC UNM (US) | 2016-02-25 | — | — | US | claimed |
| US-9132120-B1 | Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers | STC.UNM (US) | 2015-09-15 | — | — | US | claimed |
| WO-2014152330-A1 | ARSENIC-BASED TREATMENT OF CANCERS AND INFLAMMATORY DISORDERS | STC.UNM (US) | 2014-09-25 | — | — | WO | claimed |
| US-20120022026-A1 | METHOD OF TREATING CANCER | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2012-01-26 | — | — | US | claimed |
| EP-1962843-B1 | USE OF PARP-1 INHIBITORS | PHARMA MAR SA (ES) | 2011-02-23 | — | — | EP | claimed |
| WO-2009114459-A2 | ANTI-NEOPLASTIC COMBINATION THERAPEUTIC REGIMEN INVOLVING CO-DISRUPTION OF PARP PATHWAY AND MRE11/RAD50/NBS1 COMPLEX AND COMPOSITONS USEFUL THEREIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | WO | claimed |
| US-20090170860-A1 | Use of PARP-1 Inhibitors | PHARMA MAR, S.A., SOCIEDAD UNIPERSONAL (ES) | 2009-07-02 | — | — | US | claimed |
| US-20060079510-A1 | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis | MAXIM PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | claimed |
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | claimed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | claimed |
| US-11944615-B2 | Combination therapy for treatment of LKB1 deficient cancers | NEW YORK UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240105279-A1 | METHODS AND SYSTEMS EMPLOYING TARGETED NEXT GENERATION SEQUENCING FOR CLASSIFYING A TUMOR SAMPLE AS HAVING A LEVEL OF HOMOLOGOUS RECOMBINATION DEFICIENCY SIMILAR TO THAT ASSOCIATED WITH MUTATIONS IN BRCA1 OR BRCA2 GENES | Genomic Testing Cooperative, LCA (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230226047-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCERS | HEALTH RESEARCH, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051517-A1 | TARGETING ABNORMAL DNA REPAIR IN THERAPY-RESISTANT BREAST AND PANCREATIC CANCERS | LIG3, PARP1, LIG1 | PARP1 2/4885PARP2 8/4885 |
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | PARP1 1/4885PARP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.